Follow
Cyxone AB
Nasdaq First North Sweden (Sweden)
Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The product candidates of the company include T20K and Rabeximod.
Sector:
HEALTH CARE
>
Biotechnology
Sector:
TECHNOLOGY
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Show archived
Type
Ticker
ISIN
Market
SHARE
CYXO
SE0007815428
Nasdaq First North Sweden
Sweden (SE)
Details of share in Cyxone AB with ticker CYXO
Status
Active
Order book id
Amount of instruments
49 080 380
Par value
0.0755
Market cap
Currency
SEK
Segment
First North
First trading date
07 Jun 2016
Terms
Type
Price
Pre-money valuation
Time
IPO
5.00 SEK
40M SEK
13 Apr - 29 Apr 2016
IPO in Cyxone AB
Market
Nasdaq First North Sweden
Subscription period
13 Apr - 29 Apr 2016
Subscription price
10.00 SEK
Price per share
5.00 SEK
Target to raise
25 000 000 SEK
Types
Pre-money valuation
40 000 000 SEK
Subscription block size
Minimum subscription
500
Record date
Offer status
Closed
Listing status
Listed
First trading date
07 Jun 2016
Issue terms
Without preferential rights.
Type
Price
Pre-money valuation
Time
Exercise
5.00 SEK
-
30 Jan - 10 Feb 2017
Option exercise terms for CYXO TO1
Former ISIN
SE0008268072
Market
Nasdaq First North Sweden
Exercise period(s)
30 Jan - 10 Feb 2017
Exercise price
5.00 SEK
Status
Closed
Issue terms
Type
Price
Pre-money valuation
Time
Exercise
5.00 SEK
-
18 Sep - 29 Sep 2017
Option exercise terms for CYXO TO2
Market
Nasdaq First North Sweden
Exercise period(s)
18 Sep - 29 Sep 2017
Exercise price
5.00 SEK
Status
Closed
Issue terms
Type
Price
Pre-money valuation
Time
New issue
2.50 SEK
49.3M SEK
08 Oct - 23 Oct 2018
Share issue in Cyxone AB
Market
Nasdaq First North Sweden
Subscription period
08 Oct - 23 Oct 2018
Subscription price
2.50 SEK
Price per share
2.50 SEK
Target to raise
49 300 000 SEK
Types
Share issue
Pre-money valuation
49 300 000 SEK
Subscription block size
Minimum subscription
Record date
Offer status
Closed
Listing status
Listed
Issue terms
Pre-emption 1:1. One (1) existing share entitles the holder to one (1) unit right and one (1) unit right gives the right to subscribe for one (1) unit. One unit comprises one (1) newly issued share and one (1) warrant.
Type
Price
Pre-money valuation
Time
Exercise
5.37 SEK
-
02 Sep - 18 Sep 2019
Option exercise terms for CYXO TO3
Former ticker
CYXO TO 3
Market
Nasdaq First North Sweden
Exercise period(s)
02 Sep - 18 Sep 2019
Exercise price
5.37 SEK
Status
Closed
Issue terms
Update: The exercise price has been set to SEK 5.37.

Each option right entitles the holder to subscribe for one (1) share during the period September 2, 2019 to September 18, 2019. The subscription price amounts to the volume-weighted price of the Company's share during the period 19 August 2019 through August 30, 2019, with a discount of 25%, but not less than SEK 3.75 per share and a maximum of SEK 7.50 per share.
Result of offer
Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced a positive outcome of the exercise of warrants of series 3 (TO3). A total of 11,622,863 warrants were exercised, corresponding to approximately 66 percent of all warrants, for subscription of 11,622,863 shares at a subscription price of 5.37 SEK per share. By the exercised warrants, Cyxone is thus allocated approximately 62.4 MSEK before issue costs.
Type
Ticker
ISIN
Market
SHARE
CYXO
SE0007815428
Nasdaq First North Sweden
Sweden (SE)
Details of share in Cyxone AB with ticker CYXO
Status
Active
Order book id
Amount of instruments
49 080 380
Par value
0.0755
Market cap
Currency
SEK
Segment
First North
First trading date
07 Jun 2016
Terms
Type
Price
Pre-money valuation
Time
IPO
5.00 SEK
40M SEK
13 Apr - 29 Apr 2016
IPO in Cyxone AB
Market
Nasdaq First North Sweden
Subscription period
13 Apr - 29 Apr 2016
Subscription price
10.00 SEK
Price per share
5.00 SEK
Target to raise
25 000 000 SEK
Types
Pre-money valuation
40 000 000 SEK
Subscription block size
Minimum subscription
500
Record date
Offer status
Closed
Listing status
Listed
First trading date
07 Jun 2016
Issue terms
Without preferential rights.
Type
Price
Pre-money valuation
Time
New issue
2.50 SEK
49.3M SEK
08 Oct - 23 Oct 2018
Share issue in Cyxone AB
Market
Nasdaq First North Sweden
Subscription period
08 Oct - 23 Oct 2018
Subscription price
2.50 SEK
Price per share
2.50 SEK
Target to raise
49 300 000 SEK
Types
Share issue
Pre-money valuation
49 300 000 SEK
Subscription block size
Minimum subscription
Record date
Offer status
Closed
Listing status
Listed
Issue terms
Pre-emption 1:1. One (1) existing share entitles the holder to one (1) unit right and one (1) unit right gives the right to subscribe for one (1) unit. One unit comprises one (1) newly issued share and one (1) warrant.
Type
Ticker
ISIN
Market
OPTION
CYXO TO1
SE0008268080
Nasdaq First North Sweden
Sweden (SE)
Details of option in Cyxone AB with ticker CYXO TO1
Status
Archived
Order book id
Amount of instruments
Market cap
Currency
SEK
First trading date
Terms
Type
Price
Pre-money valuation
Time
Exercise
5.00 SEK
-
30 Jan - 10 Feb 2017
Option exercise terms for CYXO TO1
Former ISIN
SE0008268072
Market
Nasdaq First North Sweden
Exercise period(s)
30 Jan - 10 Feb 2017
Exercise price
5.00 SEK
Status
Closed
Issue terms
Type
Ticker
ISIN
Market
OPTION
CYXO TO2
SE0008268080
Nasdaq First North Sweden
Sweden (SE)
Details of option in Cyxone AB with ticker CYXO TO2
Status
Archived
Order book id
Amount of instruments
Market cap
Currency
SEK
First trading date
Terms
Type
Price
Pre-money valuation
Time
Exercise
5.00 SEK
-
18 Sep - 29 Sep 2017
Option exercise terms for CYXO TO2
Market
Nasdaq First North Sweden
Exercise period(s)
18 Sep - 29 Sep 2017
Exercise price
5.00 SEK
Status
Closed
Issue terms
Type
Ticker
ISIN
Market
OPTION
CYXO TO3
SE0011751817
Nasdaq First North Sweden
Sweden (SE)
Details of option in Cyxone AB with ticker CYXO TO3
Status
Archived
Order book id
165516
Amount of instruments
17 735 034
Market cap
Currency
SEK
Segment
First North
First trading date
Terms
Update: The exercise price has been set to SEK 5.37.

Each option right entitles the holder to subscribe for one (1) share during the period September 2, 2019 to September 18, 2019. The subscription price amounts to the volume-weighted price of the Company's share during the period 19 August 2019 through August 30, 2019, with a discount of 25%, but not less than SEK 3.75 per share and a maximum of SEK 7.50 per share.
Type
Price
Pre-money valuation
Time
Exercise
5.37 SEK
-
02 Sep - 18 Sep 2019
Option exercise terms for CYXO TO3
Former ticker
CYXO TO 3
Market
Nasdaq First North Sweden
Exercise period(s)
02 Sep - 18 Sep 2019
Exercise price
5.37 SEK
Status
Closed
Issue terms
Update: The exercise price has been set to SEK 5.37.

Each option right entitles the holder to subscribe for one (1) share during the period September 2, 2019 to September 18, 2019. The subscription price amounts to the volume-weighted price of the Company's share during the period 19 August 2019 through August 30, 2019, with a discount of 25%, but not less than SEK 3.75 per share and a maximum of SEK 7.50 per share.
Result of offer
Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced a positive outcome of the exercise of warrants of series 3 (TO3). A total of 11,622,863 warrants were exercised, corresponding to approximately 66 percent of all warrants, for subscription of 11,622,863 shares at a subscription price of 5.37 SEK per share. By the exercised warrants, Cyxone is thus allocated approximately 62.4 MSEK before issue costs.
People
Number of Employees
2 people
Kjell Göran Stenberg
CEO
Bert Roland Kari Junno
Chairman of the board
Bert Roland Kari Junno
Board member
Theresa Comiskey Olsen
Board member
Saad Urrehman Gilani
Board member
Mikael Lindstam
Board member
Company Details
Sector
HEALTH CARE, TECHNOLOGY

Address
Adelgatan 21
Zip code
211 22
City/district
Malmö
Country
Sweden (SE)
Registration number
559020-5471
LEI code
54930034OH16ROAY4K87
First trade date
07 Jun 2016
Registration date
13 Jul 2015
Short name
Cyxone

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More